PhaseⅠClinical Trial of Cisplatin Metronomic Chemotherapy Combined with Radiotherapy in Locoregionally Mid-late Stage Nasopharyngeal Carcinoma

Objective To explore the phaseⅠclinical dose of cisplatin in the combination of cisplatin metronomic chemotherapy and radiotherapy for locoregionally mid-late stage nasopharyngeal carcinoma, and to evaluate the treatment tolerance and anti-angiogenic effects. Methods PhaseⅠclinical trial of cisplatin metronomic chemotherapy was performed twice a week, in order to determine the maximum tolerance dose(MTD) of cisplatin when combined with radiotherapy to treat locoregionally mid-late stage nasopharyngeal carcinoma. CT perfusion scan was used to evaluate the microcirculatory change of tumor tissue before, during and after treatment. Results The MTD of cisplatin was 8 mg/m² in twice-weekly cisplatin metronomic chemotherapy combined with radiotherapy. Changes of CT perfusion scanning parameters were greater in combination therapy than that in radiotherapy alone. Conclusion Cisplatin metronomic chemotherapy combined with radiotherapy are well tolerable in locoregionally mid-late stage nasopharyngeal carcinoma. Cisplatin metronomic chemotherapy has the effect of anti-angiogenesis on nasopharyngeal carcinoma.